Analysts Set Definium Therapeutics, Inc. (NASDAQ:DFTX) PT at $35.70

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have earned a consensus rating of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $35.70.

Several analysts recently weighed in on the stock. Wolfe Research assumed coverage on shares of Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, January 5th. Robert W. Baird set a $37.00 price target on shares of Definium Therapeutics in a report on Thursday, January 29th. Royal Bank Of Canada lifted their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Finally, JonesTrading assumed coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price target on the stock.

Institutional Trading of Definium Therapeutics

Several large investors have recently added to or reduced their stakes in DFTX. Marshall Wace LLP boosted its holdings in Definium Therapeutics by 31.9% in the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock valued at $22,204,000 after acquiring an additional 828,067 shares in the last quarter. Commodore Capital LP boosted its holdings in Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after acquiring an additional 475,000 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Definium Therapeutics in the third quarter valued at $4,337,000. Rosalind Advisors Inc. boosted its holdings in Definium Therapeutics by 78.6% in the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after acquiring an additional 330,000 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Definium Therapeutics by 424.9% in the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after acquiring an additional 239,965 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Stock Up 0.7%

Shares of Definium Therapeutics stock opened at $20.58 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29. Definium Therapeutics has a 52-week low of $4.70 and a 52-week high of $21.09. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -9.66 and a beta of 2.44. The company’s 50 day moving average price is $17.88 and its 200-day moving average price is $14.57.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.